1. Volume 146, Issue 3, Pages 504-513 (September 2017)
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 
Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi 
Gynecologic Oncology 
Volume 146, Issue 3, Pages (September 2017)
DOI: /j.ygyno
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1 Flow diagram of study search and selection.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Forest plot of the association between endocrine therapy by type of drug and summary clinical benefit rate (SCBR) in ovarian cancer.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Forest plot of the association between endocrine therapy by hormone receptors status and summary clinical benefit rate (SCBR) in ovarian cancer.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

5. Fig. 4
Forest plot of the association between endocrine therapy by responsiveness to platinum-based chemotherapy and summary clinical benefit rate (SCBR) in ovarian cancer.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

6. Fig. 5
Forest plot of the association between endocrine therapy and summary estimate for death risk stratified by first line regimen.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

7. Fig. 6
Forest plot of the association between endocrine therapy and summary estimate for death risk stratified by tumor grade.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

8. Supplementary Fig. 1
Forest plot of the association between endocrine therapy by tamoxifen dose and summary clinical benefit (SCBR) in ovarian cancer.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions